Ashland Projects Earnings Recovery After Fiscal 2026 Decline
Nov 10, 2026
Ashland Global Holdings forecasts an earnings recovery in fiscal 2027 following a 2026 decline, driven by improved productivity and demand for pharmaceutical and personal care ingredients. Sales projections range from $1.905 billion to $1.975 billion with adjusted EBITDA between $405 million and $435 million.